D. Gliddon

发表

In vitro cytokine release assays: reducing the risk of adverse events in man.

C. Kirton, G. Bannish, D. Gliddon, 2011, Bioanalysis.

Investigating Immune Gene Signatures in Peripheral Blood from Subjects with Allergic Rhinitis Undergoing Nasal Allergen Challenge

Young Woong Kim, S. Tebbutt, M. Larché, 2017, The Journal of Immunology.

Co-stimulation and modulation of the ensuing immune response.

S. Stephens, J. Hope, D. Gliddon, 2002, Veterinary immunology and immunopathology.

Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies.

Neil Spooner, Amanda Wilson, Sally Robinson, 2014, Drug discovery today.

DEC‐205 expression on migrating dendritic cells in afferent lymph

J. Hope, D. Gliddon, C. Howard, 2004, Immunology.

Proceedings of the Canadian society of allergy and clinical immunology annual scientific meeting 2015

Young Woong Kim, William H. Yang, L. Liang, 2016, Allergy, Asthma & Clinical Immunology.

Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions.

Raegan B O'Lone, J. Mitchell, C. Grimaldi, 2016, Cytokine.

Inhaled biopharmaceutical drug development: nonclinical considerations and case studies

C. Kirton, M. Mcelroy, D. Gliddon, 2013, Inhalation toxicology.

FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

L. Young, Sarah Batey, N. Brewis, 2020, Clinical Cancer Research.

CD26 is expressed on a restricted subpopulation of dendritic cells in vivo

D. Gliddon, C. Howard, 2002, European journal of immunology.

FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models

Sarah Batey, N. Brewis, D. Gliddon, 2020, Clinical Cancer Research.

Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses

L. Young, N. Brewis, J. Doody, 2018, Immunology.

395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy

P. LoRusso, S. Hu-Lieskovan, K. Papadopoulos, 2020 .

A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance.

P. LoRusso, L. Young, S. Hu-Lieskovan, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies.

Kathryn L Chapman, Amanda Wilson, N. Spooner, 2014, Drug discovery today.